Avexa's Apricitabine Clinical Trial Update
MELBOURNE, Australia--(BUSINESS WIRE)--Jul 5, 2007 - Australianbiotechnology company Avexa (ASX:AVX) announced today thecompletion of apricitabine's controlled, double blinded phase whichrepresents the first 24 week segment of its Phase IIb trial.Patients have now progressed into the open-label section of thetrial (weeks 24 to 48) and will continue to receive 800mgapricitabine twice a day a...Avexa Reports Positive Phase IIb Result
VICTORIA, Australia--(BUSINESS WIRE)--Mar 20, 2007 - Australianbiotechnology company Avexa (ASX:AVX) today announced highlysuccessful results from its Phase IIb trial for apricitabine (ATC).ATC is Avexa's novel nucleoside reverse transcriptase inhibitor(NRTI) being developed for the treatment of HIV infection inpatients with drug-resistant HIV. The Phase IIb trial compared the effectivene...